Multiple Myeloma Hub
The Multiple Myeloma Hub is an open-access online resource, dedicated to providing healthcare professionals with balanced, credible, and up-to-date medical education in multiple myeloma. Our aim is to enhance knowledge in multiple myeloma through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.
The Multiple Myeloma Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by pharmaceutical companies; a full list of our supporters can be found on our website multiplemyelomahub.com. The funders are allowed no direct influence on our content.
Clinical experience with belantamab mafodotin: Management strategies for ocular toxicity
MIDAS: MRD-driven strategy after Isa-KRd induction in ND ASCT-eligible MM
How might the clinical development of CELMoDs impact the treatment paradigm for MM?
CARTITUDE-2: Cilta-cel ± Len maintenance for MM with suboptimal response to ASCT
Evolving diagnostic criteria for high-risk smoldering MM
Risk stratification and prognosis in smoldering MM
What combination regimens including BiTEs are being evaluated for the treatment of RRMM?
What combination regimens containing BCMA-directed bispecific antibodies are being evaluated for MM?
How can neurotoxicity associated with CAR T-cell therapy in MM be managed?
What might be the future applications for BCMA-directed bispecific antibodies in MM and other PCD?
What are the unmet needs in high-risk smoldering multiple myeloma?
What are the future perspectives for the treatment of high-risk smoldering MM?
MRD in MM: Implications for clinical practice and trial design
Targeting XPO1 for the treatment of MM: Real-world evidence
How are BCMA-directed bispecific antibodies currently utilized in real-world practice for MM?
How to incorporate novel therapies into the treatment paradigm for early RRMM?
What are the future perspectives for anti-CD38 mAbs in the treatment of MM?
What are the current treatment recommendations and unmet needs in early RRMM?
What is the rationale for treating early RRRM with targeted therapies?
What is the impact of belantamab mafodotin on QoL in patients with MM?
What is the clinical experience with elranatamab for the treatment of multiple myeloma?
What are the latest updates from clinical trials of isatuximab for NDMM?
What is the impact of elranatamab on quality of life in relapsed/refractory multiple myeloma?
Belantamab mafodotin combination therapies in early RRMM
Symposium | Panel discussion | Strategies for the management of treatment-related toxicities in MM
Symposium | BCMA-directed ADCs for the treatment of MM
Symposium | Treatment paradigm in early RRMM
Symposium | How to sequence BCMA-directed therapies in RRMM
How do I treat patients who have relapsed after quadruplet regimen in the first-line in MM?
How do I treat patients with RRMM after failure of BCMA-targeted therapies?